Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study

Lexaria Bioscience (LEXX) announced that its Contract Research Organization has completed the important study milestone known as last patent last visit in Lexaria’s Phase 1b glucagon-like peptide-1 study in Australia, GLP-1-H24-4. The Study CRO is actively managing the laboratory analysis phase of the work, where thousands of samples collected during the Study are being carefully processed, analysed, and recorded into an extensive database recording system. Lexaria is blinded to that data until the database work has been completed. Lexaria previously released partial 8-week positive interim results from the Study with encouraging results aligned with its primary study endpoint. These interim results were tracking very nicely from a safety and tolerability perspective relative to the Rybelsus control arm of the Study; most notably in terms of reductions in the incidence of gastrointestinal adverse events.